Effects of FK317, a novel anti-cancer agent, on survival of mice bearing B16BL6 melanoma and Lewis lung carcinoma.
The effects of FK317 (11-acetyl-8-carbamoyloxymethyl-4-formyl-6-methoxy-14- oxa-1,11-diazatraacylo[7.4.1.0(2.7).0(10.2)]-tetradeca-2,4,6-trien-9-yl acetate), a novel anti-cancer agent, and mitomycin C (MMC) on survival time of mice bearing B16BL6 melanoma and Lewis lung carcinoma (LLC), induced by intravenous inoculation of the tumor, were investigated. Treatment with FK317 resulted in a significant prolongation of survival time in both tumor models. Four of ten mice bearing B16BL6 were disease-free following FK317 treatment. In contrast, MMC was not effective in prolonging survival time. Overall, this study demonstrated that FK317 shows more potent survival extension in mice bearing B16BL6 and LLC than MMC, suggesting that FK317 may have therapeutic utility for cancer chemotherapy.
Inami
Masamichi
M
Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan.
Kawamura
Ikuo
I
Tsujimoto
Susumu
S
Nishigaki
Fusako
F
Matsumoto
Sanae
S
Naoe
Yoshinori
Y
Sasakawa
Yuka
Y
Matsuo
Masahiko
M
Manda
Toshitaka
T
Goto
Toshio
T
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D008546:Melanoma, Experimental / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D016685:Mitomycin / Q000627:therapeutic use; D010078:Oxazines / Q000627:therapeutic use*; D016019:Survival Analysis
D000970:Antineoplastic Agents; D010078:Oxazines; D016685:Mitomycin; C112463:FK 317 dihydrobenzoxazine